AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 51 min read$TEVA

Hughes Eric A sold $892K of TEVA

Hughes Eric A (See "Remarks") sold 25,578 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.88 ($0.89M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hughes Eric A
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEVA
Neutral
medium confidence
Mentioned
$TEVA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider activity but does not include new fundamentals, guidance, litigation, or operational changes.

02

Market read

Traders may note insider selling, but the 10b5-1 structure makes it a low-conviction catalyst.

03

What to watch

Insider sales can be routine for diversification or tax planning; without additional context (e.g., option exercises, other concurrent filings), directional inference is weak.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

SEC Form 4 insider transaction for TEVA, reported as an open-market sale by an officer under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$TEVANeutralMedium confidence
Context

TEVA insider Form 4 shows Hughes Eric A sold 25,578 shares at $34.8757 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Limited near-term impact; any effect is likely sentiment-only and outweighed by the plan structure.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan, reducing interpretive value versus unscheduled sales.

Market effects

Sector

No clear sector read-through from a single 10b5-1 insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be purely liquidity-driven and not a bearish signal, especially given the pre-arranged 10b5-1 plan.

Key entities

  • issuer
    TEVA PHARMACEUTICAL INDUSTRIES LTD

    Subject of the Form 4 insider sale disclosure.

  • insider
    Hughes Eric A

    Officer who sold 25,578 shares at $34.8757 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

OCT 13
$TEVAHigh

Teva wins FDA approval for schizophrenia injection

Teva Pharmaceuticals received FDA approval for a new injection form of olanzapine, an antipsychotic drug for schizophrenia. The company claims this could improve patient adherence compared to daily oral treatment, potentially reducing relapse risks. Olanzapine is the most widely prescribed atypical antipsychotic.

lifesciencesweden.se1 min
OCT 13
$TEVAHigh

USFDA Approves Teva's Once-Monthly Schizophrenia Injection Weltruza

Teva, in partnership with Medincell, received USFDA approval for Weltruza, a once-monthly schizophrenia injection. Teva expects to launch the drug in the US soon. Medincell's technology enables extended-release medication. Analysts note potential for improved treatment adherence. Medincell may receive up to $112 million in milestone payments and royalties. Teva's shares rose 2% in Tel Aviv; Medincell's shares gained 16.9% in Paris.

medicaldialogues.in2 min
OCT 12
$TEVAHigh

FDA Approves Once-Monthly Olanzapine Injection for Adults with Schizophrenia

The FDA approved Teva Pharmaceuticals' once-monthly olanzapine injection (Weltruza) for adults with schizophrenia. The subcutaneous injection uses novel technology for steady release, eliminating post-injection monitoring. The approval was based on the Phase 3 SOLARIS trial, showing significant symptom reduction and a safety profile consistent with oral olanzapine.

drugtopics.com3 min
OCT 12
$TEVAHigh

FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine injection, received FDA approval for treating schizophrenia. The treatment requires no loading doses or postinjection monitoring. It will be available in doses of 318 mg, 425 mg, and 531 mg, corresponding to daily oral olanzapine doses. The approval was based on the SOLARIS trial, which showed significant improvements in symptoms compared to placebo.

pharmacytimes.com3 min
OCT 12
$TEVAMed

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva Pharmaceutical Industries received FDA approval for Weltruza, a once-monthly injection for schizophrenia. Shares rose 4.7% on Oct. 9. The drug will launch in the U.S. soon, offering an alternative to daily oral treatments. Teva's Uzedy, another schizophrenia treatment, saw sales surge 51% YoY to $140M in H1 2026. Teva also progresses with its branded pipeline, including duvakitug for inflammatory bowel diseases.

zacks.com6 min